ArticleCell & bioscience2026
Overexpression of ONECUT1 suppresses hepatoblastoma progression via modulating tumor cell growth and tumor microenvironment.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundHepatoblastoma is the most common malignant liver tumor in children. Our previous work showed that enforced expression of the transcription factor One Cut Homeobox 1 (ONECUT1) suppresses the initiation of hepatoblastoma. However, it remains unclear whether increasing ONECUT1 expression can also inhibit tumor progression after tumors have already formed. The purpose of this study was to determine the effects of ONECUT1 induction on tumor cell behavior and tumor growth during established hepatoblastoma progression.
resultsWe generated doxycycline-inducible expression systems to upregulate ONECUT1 in hepatoblastoma cells in culture and in mouse models. In human hepatoblastoma cells, induction of ONECUT1 promoted apoptotic cell death and reduced cell cycle progression. In a subcutaneous xenograft model using immunodeficient mice, ONECUT1 induction slowed tumor growth but did not cause tumor regression. We then established an orthotopic HB model in FVB/N mice by tail-vein injection of YAP/β-catenin/TRE-ONECUT1 plasmids. ONECUT1 expression in existing mouse HB cells was induced by feeding the mice with DOX-water. Remarkably, tumor regression was observed following ONECUT1 induction. Histological analyses showed extensive necrosis and apoptosis in tumor lesions following induction of ONECUT1, accompanied by robust macrophage infiltration and moderate T cell infiltration. Depletion of T cells using antibodies against CD4 and CD8 weakened the antitumor effect of ONECUT1, indicating that T-cell activity contributes to tumor suppression. Transcriptomic analysis further suggested that ONECUT1 may promote antitumor immune responses in part by increasing expression of immune-related cytokines.
conclusionsInduction of ONECUT1 suppresses hepatoblastoma progression by inhibiting tumor cell growth and by reshaping the tumor immune microenvironment. These findings reveal a previously unrecognized antitumor role of ONECUT1 during hepatoblastoma progression and suggest that restoring ONECUT1 activity may represent a promising therapeutic strategy for this pediatric malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.